
Study Title:
MAGRIT 109493: A double-blind, randomized,
placebo-controlled Phase III study to assess the efficacy of recMAGE-A3
+ AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in
patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer
What is the purpose of this study?
The purpose of this study is to determine whether adding a vaccine
to boost immune response in conjunction with chemotherapy and surgery
will prove to be clinically effective (resulting in disease free survival)
in patients diagnosed with lung cancer.
Am I a candidate for this study?
What do I have to do?
Why should I participate?
If you are interested in participating in this
lung cancer research study, please contact:
Kristin Sorensen, MS, RN, clinical research nurse
sorenk@holycrosshealth.org
301.754.7961
Principle Investigator: Kashif Firozvi, MD, medical
oncologist
Co-investigator: Lawrence Markovitz, MD thoracic surgeon